The numbers are stark: thyroid cancer incidence in the United States has tripled since 1975, rising from roughly 4.8 to 14.2 cases per 100,000 people. Yet the death rate from the disease has barely budged, hovering around 0.5 per 100,000. For a growing number of epidemiologists and endocrinologists, that discrepancy points to one explanation: overdiagnosis. The medical community is increasingly divided on what to do about it.

Thyroid Cancer Rates Have Tripled — but Is It Really a Health Crisis?

The rise in thyroid cancer diagnoses is almost entirely driven by small papillary cancers, many measuring under one centimeter. Dr. H. Gilbert Welch, a prominent researcher on overdiagnosis, has called this an epidemic of detection rather than disease. In a widely cited 2014 study, Welch and colleagues estimated that roughly 70 to 80 percent of new thyroid cancer cases in women and 45 percent in men represented overdiagnosis — cancers that would never have caused symptoms or death if left undetected.

Autopsy studies lend support: between 10 and 30 percent of people who die from other causes are found to harbor a thyroid cancer at autopsy, most of them tiny and confined to the gland. The implication is that a large reservoir of indolent tumors exists in the population, and modern imaging simply pulls them into clinical attention.

Mortality trends reinforce the overdiagnosis hypothesis. Despite the tripling of incidence, the US thyroid cancer death rate has remained essentially flat for decades. If the new cases represented true disease, some uptick in deaths would be expected, even with improved treatment. The lack of such a rise suggests that most of the newly diagnosed cancers are biologically harmless.

Critics of the overdiagnosis narrative argue that some of the incidence increase may reflect real environmental or lifestyle factors, such as rising obesity rates or increased radiation exposure from medical imaging. For example, obesity is associated with higher levels of thyroid-stimulating hormone, which may promote tumor growth. However, the magnitude and pattern — a near-exclusive rise in small papillary tumors — is more consistent with detection bias than a true epidemic. Moreover, studies that adjust for obesity and radiation exposure still find a large residual increase attributable to overdiagnosis.

Another counterpoint comes from pathologists who note that the diagnostic threshold for papillary microcarcinoma has lowered over time. In the past, some tiny lesions were classified as benign or as incidental findings of no clinical significance. Today, they are more likely to be labeled as cancer. This change in diagnostic criteria alone can account for a portion of the incidence increase. The World Health Organization's classification of thyroid tumors has been revised multiple times, each time potentially expanding the definition of malignancy.

The Asymptomatic Nodule: A Modern Medical Dilemma

High-resolution ultrasound can now detect thyroid nodules in roughly 50 percent of adults, the vast majority of which are benign. When a nodule is found, the standard next step is fine-needle aspiration biopsy. But cytology has limits: up to 30 percent of biopsies yield indeterminate results, leaving clinicians and patients in a gray zone. Molecular tests such as ThyroSeq and Afirma can help reclassify some of these, but they are not perfect and add cost. ThyroSeq, for instance, analyzes a panel of genetic mutations associated with thyroid cancer, while Afirma uses gene expression classifiers. Both can reduce the number of unnecessary surgeries, but false positives and false negatives still occur. A patient with a benign molecular result may still harbor a cancer that the test missed, while a suspicious result may lead to surgery for a nodule that is ultimately benign.

The experience in South Korea is instructive. After the country launched a nationwide screening program in the late 1990s, thyroid cancer incidence shot up 15-fold. The vast majority of new cases were papillary microcarcinomas, and mortality did not change. The Korean experience is often cited as a cautionary tale: screening turned millions of people into patients, many of whom underwent unnecessary surgery and lifelong thyroid hormone replacement. In response, South Korea revised its guidelines to discourage screening in asymptomatic adults, and incidence rates have since plateaued and begun to decline.

In the US, screening is not officially recommended, but incidental detection happens all the same. A patient who gets a carotid ultrasound for stroke risk or a CT scan for an unrelated issue may walk away with an incidental thyroid nodule. From there, the cascade of further testing and treatment can be hard to stop. Some clinicians now advocate for a more conservative approach: if a nodule is small and looks benign on ultrasound, simply monitor it. The American College of Radiology's Thyroid Imaging Reporting and Data System (TI-RADS) provides a standardized way to assess nodule risk based on ultrasound features, helping to guide decisions about biopsy. TI-RADS assigns points for composition, echogenicity, shape, margin, and echogenic foci, and categorizes nodules from TR1 (benign) to TR5 (highly suspicious). This system aims to reduce unnecessary biopsies while still catching aggressive cancers.

The dilemma is that no one wants to miss a rare aggressive cancer. But the data suggest that most small nodules are not aggressive. Balancing reassurance with vigilance is the central challenge of modern thyroid nodule management. A 2020 study in JAMA Internal Medicine found that among patients with thyroid nodules smaller than 1 cm, the risk of cancer progression over 5 years was less than 2 percent. Yet many of these patients still undergo biopsy and surgery. The psychological burden of living with a known nodule can be significant, but so can the burden of unnecessary treatment.

Why Experts Split on Active Surveillance vs. Immediate Surgery

Active surveillance — monitoring a known cancer with serial ultrasounds and intervening only if it grows — has been studied most extensively in Japan. The Kuma Hospital in Kobe and the University of Tokyo have followed cohorts of patients with papillary microcarcinoma for over a decade. Results show 10-year disease-specific survival exceeding 99 percent among those who chose surveillance, with only about 2 to 5 percent of patients showing tumor progression at five years. In the Kuma cohort, which includes more than 3,000 patients, the rate of lymph node metastasis during surveillance is similarly low, and when progression occurs, salvage surgery is almost always effective.

In the United States, uptake of active surveillance has been slower, but it is gaining traction. The American Thyroid Association's 2015 guidelines endorsed active surveillance as a reasonable option for low-risk papillary microcarcinoma, and a growing number of academic centers now offer it. Yet many community endocrinologists and surgeons still recommend surgery, citing patient anxiety and medicolegal concerns. A survey of US endocrinologists published in 2019 found that only about 40 percent would recommend active surveillance for a 45-year-old patient with a 6 mm papillary microcarcinoma. The rest favored surgery, often total thyroidectomy.

Surgery carries its own risks. Total thyroidectomy, once the standard for any thyroid cancer, can damage the parathyroid glands (causing permanent hypoparathyroidism in about 2 percent of cases) or the recurrent laryngeal nerve (causing voice hoarseness in about 1 percent). Even lobectomy, which spares half the gland, carries some surgical risk and may require thyroid hormone replacement if the remaining lobe cannot produce enough hormone. The risk of hypoparathyroidism after total thyroidectomy is higher in low-volume centers, suggesting that surgeon experience matters. Patients who undergo total thyroidectomy also face a small risk of bleeding or infection, and they must take daily thyroid hormone replacement for life, with periodic blood tests to ensure proper dosing.

Patient preferences vary widely. Some individuals find the idea of living with an untreated cancer psychologically intolerable, no matter how low the risk. Others are relieved to avoid surgery. Shared decision-making, using decision aids and risk calculators, is increasingly recommended to help patients weigh their options. A decision aid developed at the Mayo Clinic, for example, presents patients with personalized estimates of the likelihood of cancer progression, surgical complications, and the need for hormone replacement. Studies show that patients who use decision aids are more likely to choose active surveillance and report higher satisfaction with their care.

Cultural factors also influence treatment choices. In Japan, active surveillance has been widely accepted for decades, partly because of a cultural emphasis on avoiding unnecessary intervention. In the US, a more interventionist medical culture, combined with fear of litigation, has slowed adoption. However, as evidence accumulates, attitudes are shifting. The 2023 American Thyroid Association guidelines are expected to strengthen the recommendation for active surveillance in low-risk patients.

The Role of the US Preventive Services Task Force (USPSTF)

In 2017, the US Preventive Services Task Force issued a D grade against screening for thyroid cancer in asymptomatic adults. The recommendation was based on moderate certainty that the harms of screening — including overdiagnosis, unnecessary surgery, and psychological distress — outweigh any potential benefit. The USPSTF noted that no randomized trial of screening versus no screening had ever been conducted, and that evidence from observational studies suggested net harm. The D grade means that clinicians should discourage screening in asymptomatic patients.

Endocrine societies, including the American Thyroid Association and the American Association of Clinical Endocrinologists, pushed back. They argued that the USPSTF recommendation was too broad and could discourage appropriate case-finding in high-risk individuals, such as those with a family history of medullary thyroid cancer or prior neck radiation. They also raised concerns about patient anxiety: if a screening test is not recommended, some patients may worry that their doctor is missing something. The societies emphasized that the recommendation should not apply to patients with symptoms, such as a palpable neck lump, or to those at high risk due to genetic syndromes like MEN2.

Litigation fears also play a role. The medicolegal environment in the US incentivizes defensive medicine. A clinician who finds a thyroid nodule and does not biopsy it may face a malpractice suit if the nodule later turns out to be aggressive. Conversely, biopsying and treating every nodule leads to overdiagnosis but rarely results in lawsuits. The asymmetry keeps the cascade going. Some experts have called for tort reform to reduce defensive medicine, but such changes are politically difficult.

Notably, the USPSTF recommendation applies only to screening in asymptomatic adults. It does not address the management of incidentally discovered nodules or of patients with symptoms. In practice, many nodules are found incidentally, so the line between screening and case-finding is blurry. For example, a patient who has a CT scan for abdominal pain and is found to have a thyroid nodule has not been screened in the traditional sense, but the same cascade of testing and treatment may follow. The USPSTF has acknowledged this gray area and called for more research on how to manage incidentalomas.

Since the 2017 recommendation, some studies have suggested that the incidence of thyroid cancer may be plateauing in the US, possibly due to more conservative diagnostic practices. However, overdiagnosis remains a significant problem, particularly in regions with high rates of imaging use. A 2022 analysis estimated that overdiagnosis accounts for roughly 60 to 70 percent of thyroid cancer cases in the US, similar to the rates reported by Welch.

Treatment De-escalation: From Total Thyroidectomy to Lobectomy

Reflecting the growing recognition of overdiagnosis, treatment for thyroid cancer has become less aggressive over the past decade. Between 2009 and 2019, the proportion of low-risk patients undergoing lobectomy rather than total thyroidectomy rose from roughly 10 percent to about 30 percent. Lobectomy removes only the affected lobe, preserving the contralateral lobe and reducing the risk of surgical complications and the need for lifelong hormone replacement. For tumors smaller than 4 cm without extrathyroidal extension, lobectomy is now considered sufficient by many guidelines.

Radioactive iodine ablation, once routinely given after thyroidectomy for any cancer larger than 1 cm, has also declined. Use of radioactive iodine fell by approximately 40 percent over the same period, as studies showed no survival benefit for low-risk patients. Radioactive iodine can cause side effects such as dry mouth, taste changes, and a small increase in the risk of secondary malignancies. The shift reflects a broader trend in oncology: doing less for patients with low-risk disease can improve quality of life without compromising outcomes.

At centers like Dana-Farber Cancer Institute, follow-up protocols have been scaled back for patients with stable disease. Instead of annual neck ultrasounds and blood tests, some patients now have scans every two to three years. The goal is to reduce the burden of surveillance on patients who are unlikely to experience recurrence. Thyroglobulin levels, which are used to detect residual or recurrent disease, are also measured less frequently in low-risk patients.

Patient advocacy groups, such as the Thyroid Cancer Survivors' Association, have called for better shared decision-making tools. They argue that patients are often not given a balanced view of the trade-offs between surgery and surveillance. Some groups have developed online risk calculators and decision aids to help patients understand their individual risk and treatment options. The ThyCa Survivors' Association, for example, offers a free online tool that estimates the likelihood of cancer progression and surgical complications based on patient age, tumor size, and other factors.

Despite these advances, treatment de-escalation has not been uniform. Some surgeons and endocrinologists remain hesitant to change their practice, citing a lack of long-term US data on active surveillance. The ongoing clinical trial comparing active surveillance to immediate surgery for papillary microcarcinoma, led by the University of Pittsburgh, may provide more definitive evidence. Results are expected within the next few years.

What This Means for Patients and Clinicians Today

For a patient diagnosed with a small thyroid nodule, the first question to ask is: Is this nodule likely to cause harm in my lifetime? The answer depends on size, ultrasound features, and the patient's age and overall health. For a 70-year-old with a 6-millimeter nodule that looks benign on ultrasound, the risk of it ever causing trouble is extremely low. For a 30-year-old with a 1.5-centimeter nodule that has suspicious features, the risk is higher but still modest. The American Thyroid Association's risk stratification system, which incorporates tumor size, extrathyroidal extension, and lymph node involvement, can help estimate the likelihood of recurrence and death.

Before agreeing to surgery, patients should consider seeking a second opinion at a high-volume center that offers active surveillance. Many academic medical centers now have dedicated thyroid nodule clinics where multidisciplinary teams — including endocrinologists, surgeons, radiologists, and pathologists — can help weigh the options. Online risk calculators, such as those based on the ThyroSeq or Afirma molecular tests, can provide additional risk stratification, though they are not perfect. A patient with a benign molecular result may still have a small risk of cancer, and a suspicious result may lead to surgery for a benign nodule.

Watchful waiting is a safe option for most microcarcinomas under 1.5 centimeters, based on long-term data from Japan and emerging US studies. Patients who choose surveillance need to commit to regular follow-up — typically an ultrasound every six to twelve months initially, then annually if stable. If the nodule grows or changes, surgery can be performed at that point with no loss of cure. Studies from Japan show that even if surgery is delayed by several years, outcomes are no worse than immediate surgery.

Patients should also consider the impact of treatment on quality of life. Total thyroidectomy requires lifelong thyroid hormone replacement, which can cause symptoms if dosing is not optimal. Some patients experience fatigue, weight changes, or mood disturbances even with normal blood tests. Lobectomy may avoid the need for hormone replacement in some patients, but not all. Active surveillance avoids these issues altogether but requires a willingness to live with uncertainty.

The debate over thyroid overdiagnosis is unlikely to be resolved soon. Reasonable people disagree on where to draw the line between appropriate caution and excessive intervention. What is clear is that the current approach, which treats nearly all detected thyroid cancers as urgent, is causing harm to many patients who would have been better off left alone. More nuanced guidelines, better risk stratification, and honest communication about uncertainty are needed. Clinicians must be willing to say, "We don't know for sure, but here is what the evidence suggests." Patients must be empowered to make choices that align with their values.

Disclaimer: This article is for informational purposes only and does not constitute personalized medical advice. Individuals should consult their healthcare provider for decisions about screening, diagnosis, and treatment.